** Shares of GH Research GHRS.O down 3.2% premarket to $15.79 after securing equity raise
** Irish biotech firm late Tues sold 10 mln shares at $15 for $150 mln gross proceeds
** Offering price represents 8.1% discount to stock's last sale of $16.32. Stock fell 9.3% on Tues
** On Mon, GHRS shares surged 70% to close at $17.99, highest since Apr 2022, after co said its depression therapy, GH001, met main goals of mid-stage study
** Co intends to use net offering proceeds to invest in research, clinical/technical development of current and/or additional product candidates, according to the SEC filing
** It has 52 mln shares outstanding for nearly $850 mln market cap
** Cantor, Stifel and RBC are jt bookrunners for the offering
** Sentiment on GHRS unanimously bullish among 5 analysts covering the stock and their median PT is $37, according to LSEG data
** Stock ended 2024 at $7
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.